


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects




Other adjustments



SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Tislelizumab in combination with pemetrexed and platinum-containing ChT is indicated for the first-line treatment of adult patients with NSCLC whose tumours have PD-L1 expression on $\geq 50\%$ of tumour cells with no EGFR or ALK positive mutations and who have: locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC
Experimental Arm: Tislelizumab + Pemetrexed + platinum-containing ChT
Control Arm: Pemetrexed + platinum-containing ChT

